Neuro Panel: Wingspan Stent’s Probable Benefits No Longer Outweigh Risks
This article was originally published in The Gray Sheet
Recent post-market study data leads FDA’s Neurological Devices panel to conclude that the intracranial stent system, which gained humanitarian device exemption approval in 2005, no longer shows probable benefits outweighing the risks.
You may also be interested in...
Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.
Group urges FDA to pull Stryker’s Wingspan stent from the market, among other regulatory updates.
Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.